The CNV assays are the latest effort by NanoString to ferret out new applications for its nCounter platform, which the company initially developed as an alternative to both qPCR and microarrays for gene expression studies.
Co-founded by Harvard physics professor David Weitz, a founder of RainDance Technologies, the startup plans to develop an inexpensive, fast, and scalable microfluidics-based sequencer, where reactions take place in picoliter-sized drops.
For early adopters, there are many reasons to be excited about the potential of whole-genome sequencing to broadly personalize healthcare. But for some public health observers, the analytical and educational challenges present an overwhelming hurdle.
By sequencing the Neandertal nuclear genome and comparing it with human and chimpanzee genomes, an international research team has gained new insights into the histories of both humans and Neandertals.
Since a US federal district court last month deemed seven of Myriad Genetics' BRCA patents invalid, certain industry players have taken small steps toward fostering more collaboration around gene patents while others have raised questions about the value of patenting genes altogether amid rapid advances in whole-genome sequencing.
Foundation Medicine has raised $25 million in Series A financing that it will use to "broadly analyze the relevant tumor genomic and other molecular information in individual patients' cancers and connect it with a knowledgebase of clinical data to help oncologists personalize treatment."
In a newsletter published last week, PGP organizers said they have now started to enroll participants for the PGP-100. Enrollment for the next phase of the project, PGP-1000, is expected to start later this year.